181 related articles for article (PubMed ID: 37805620)
21. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
22. The status of jaw lesions and medication-related osteonecrosis of jaw in patients with multiple myeloma.
Lu SY; Ma MC; Wang MC; Hsue SS
J Formos Med Assoc; 2021 Nov; 120(11):1967-1976. PubMed ID: 33551311
[TBL] [Abstract][Full Text] [Related]
23. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
[TBL] [Abstract][Full Text] [Related]
24. Medication-related osteonecrosis of the jaws: a single centre, Far North Queensland case series.
Smith S; Finn B; Goss AN
Aust Dent J; 2022 Jun; 67(2):168-171. PubMed ID: 35199861
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Medication-Related Osteonecrosis of the Jaw: Controversies in Causality and Therapy.
Halpern LR; Adams DR
Dent Clin North Am; 2024 Jan; 68(1):67-85. PubMed ID: 37951638
[TBL] [Abstract][Full Text] [Related]
26. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of pathological characteristics of medication-related osteonecrosis of the jaw and discussion of clinical treatment strategies based on the pathological analysis results].
Guo YX; Zhang JY; Wang DC; Guo CB
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1190-1195. PubMed ID: 36533354
[TBL] [Abstract][Full Text] [Related]
28. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
Aljohani S; Fliefel R; Ihbe J; Kühnisch J; Ehrenfeld M; Otto S
J Craniomaxillofac Surg; 2017 Sep; 45(9):1493-1502. PubMed ID: 28687467
[TBL] [Abstract][Full Text] [Related]
29. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
Kawahara M; Kuroshima S; Sawase T
Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
[TBL] [Abstract][Full Text] [Related]
30. Case series of medication-related osteonecrosis of the jaw (MRONJ) patients prescribed a drug holiday.
Hamid A; Thomas S; Bell C; Gormley M
Br J Oral Maxillofac Surg; 2023 Apr; 61(3):227-232. PubMed ID: 36935312
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetics of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis.
Guo Z; Cui W; Que L; Li C; Tang X; Liu J
Int J Oral Maxillofac Surg; 2020 Mar; 49(3):298-309. PubMed ID: 31445964
[TBL] [Abstract][Full Text] [Related]
32. Medication-related osteonecrosis of the jaw without osteolysis on computed tomography: a retrospective and observational study.
Sakamoto Y; Sawada S; Kojima Y
Sci Rep; 2023 Aug; 13(1):12890. PubMed ID: 37558709
[TBL] [Abstract][Full Text] [Related]
33. "Spontaneous" medication-related osteonecrosis of the jaw; two case reports and a systematic review.
Khominsky A; Lim M
Aust Dent J; 2018 Dec; 63(4):441-454. PubMed ID: 30144095
[TBL] [Abstract][Full Text] [Related]
34. Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.
Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
J Formos Med Assoc; 2021 Aug; 120(8):1572-1580. PubMed ID: 33309430
[TBL] [Abstract][Full Text] [Related]
35. Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study.
Wazzan T; Kashtwari D; Almaden WF; Gong Y; Chen Y; Moreb J; Katz J
Spec Care Dentist; 2018 Nov; 38(6):356-361. PubMed ID: 30194738
[TBL] [Abstract][Full Text] [Related]
36. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
[TBL] [Abstract][Full Text] [Related]
37. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
[TBL] [Abstract][Full Text] [Related]
38. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
Hasegawa T; Hayashida S; Kondo E; Takeda Y; Miyamoto H; Kawaoka Y; Ueda N; Iwata E; Nakahara H; Kobayashi M; Soutome S; Yamada SI; Tojyo I; Kojima Y; Umeda M; Fujita S; Kurita H; Shibuya Y; Kirita T; Komori T;
Osteoporos Int; 2019 Jan; 30(1):231-239. PubMed ID: 30406309
[TBL] [Abstract][Full Text] [Related]
39. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O; Peter JU
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012432. PubMed ID: 35866376
[TBL] [Abstract][Full Text] [Related]
40. [Therapeutic alternatives for drug-associated maxillary osteonecrosis (MRONJ): reports of two clinical cases and review of the literature].
Leonardi N; Gilligan G; Piemonte E; Panico R
Rev Fac Cien Med Univ Nac Cordoba; 2022 Dec; 79(4):379-382. PubMed ID: 36542580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
